New hope for tough pancreatic cancers: testing targeted drug combos
NCT ID NCT06783140
Summary
This study is testing which of two different drug combinations works better for people with advanced pancreatic cancer that has specific genetic changes (BRCA1, BRCA2, or PALB2 mutations) and has stopped responding to their first treatment. It will compare a newer combination called NABPLAGEM against the standard combination of nab-paclitaxel and gemcitabine. The main goals are to see which treatment helps patients live longer and shrinks tumors more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALB2 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.